You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on ovarian cancer.
With the PARIS test, researchers identified several targeted agents that could help patients overcome PARP inhibitor resistance and may be worth further study.
The study, presented at the NSGC annual conference last week, supports the broader use of panel testing for cancer patients suspected of hereditary disease.
The company has used its semi-closed electroporation system to manufacture autologous CAR T cells to treat ovarian cancer and leukemia patients in two trials.
A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.
Regulators approved the PARP inhibitor as a monotherapy for BRCA1/2-mutated mCRPC and together with Avastin for advanced, HRD-positive ovarian cancer.
A Phase I study used a less toxic dosing schedule that yielded encouraging response rates in patients with difficult-to-treat KRAS-mutated cancers.
FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer.
The Broad Institute's CRISPR paralog screening platform will inform Ideaya's synthetic lethality-based target and biomarker discoveries.
The firm will conduct genomic and transcriptomic analysis to identify predictors of response to the personalized immunotherapy TG4050.
The decision is based on data from the PAOLA-1 trial, which focused on patients with tumors that have homologous repair recombination deficiency.